Table 2 Possible treatment modifications based on MRI after neoadjuvant therapy (MRI2) and its requirements.
Treatment modifications were primarily increase in sedation or fluid challenge, which should perhaps change our attitude.
Toxicity was primarily constitutional, and treatment modifications were designed to maintain toxicity at grade 2/3.
Etiology, inflammatory response to infection, antibiotic treatment (ATB T), and treatment modifications according to culture results, was analyzed.
Mycological results were the main drivers for treatment modifications, which occurred in almost half of the targeted SATs.
Treatment interruptions lasting less than 15 days were considered as treatment modifications.
We hypothesized that by the use of personalized models, we can suggest treatment modifications to stabilize PSA levels.
Further, we wanted to describe the frequency of treatment modifications and discontinuations, as well as the clinical course.
With increased access to cART, drug stock-outs related to insufficient human resources and poor infrastructure have been reported, leading to treatment modifications or discontinuations [5], [6], [7].
Finally, as shown in previous studies, treatment modifications that were not related to drug stock-outs were independently associated with death [10], [12], [33].
CATEGORY 3: Intervention or treatment modifications necessary.
